Subanesthetic-dose esketamine-assisted electroconvulsive therapy for suicidal ideation in adolescents with major depressive disorder: Interim trial results
Year: 2026
Type: article
Abstract: BACKGROUNDEvidence for adjunctive subanesthetic-dose esketamine during electroconvulsive therapy (ECT) in adolescents with major depressive disorder (MDD) is limited.Suicidal ideation is a critical early treatment target in this population.We hypothesized that adjunctive subanesthetic-dose esketamine during ECT would accelerate the reduction in suicidal ideation and improve early clinical outcomes. AIMTo evaluate the efficacy and safety of adjunctive subanesthetic-dose esketamine during ECT in adolescents with MDD. METHODSThis interim report presents a randomized, double-blind, controlled trial of 113 adolescents aged 13-17 with MDD undergoing ECT.Participants were randomized 1:1 to esketamine (0.25 mg/kg) plus propofol (n = 56) or saline plus propofol (n = 57).The key outcome was early change in suicidal ideation via the Beck Scale for Suicide Ideation.Additional outcomes, including depressive and psychopathological symptoms, cognitive performance, response, remission, and safety, were also assessed.Intention-to-treat and per-protocol analyses were performed. RESULTSAdjunctive esketamine was associated with different longitudinal trajectories of suicidal ideation, with a group × time interaction (F = 95.27,P < 0.001, partial η 2 = 0.553).A higher response rate was observed in the esketamine group [76.8% vs 57.9%; adjusted odds ratio = 2.49, 95% confidence interval (CI): 1.08-5.75],although remission rates were similar.The 24-item Hamilton Depression Rating Scale scores were lower after four ECT sessions (P 4 / 43 = 0.013), while the 9-item Patient Health Questionnaire and modified Positive and Negative Syndrome Scale scores reduced during treatment (both P < 0.001).Montreal Cognitive Assessment scores were higher (adjusted mean difference = 1.24, 95%CI: 0.57-1.91,P < 0.001).Injection pain occurred less frequently (10.7% vs 33.3%, P = 0.004), with no differences in other adverse events. CONCLUSIONAdjunctive subanesthetic-dose esketamine during ECT accelerates the reduction in suicidal ideation and improves early depressive and psychopathological symptoms in adolescents with MDD.No significant short-term cognitive decline was observed; longterm outcomes remain uncertain.
Source: World Journal of Psychiatry
DOI: 10.5498/wjp.124685
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
Funder: Chongqing Medical University
OpenAlex ID: W7223103183
FWCI:
Cites:
Cited by:
Related to: